The Native Antigen Company Expands Into New Facilities
Dr Nick Roesen, CSO, The Native Antigen Company
The Native Antigen Company has announced that it has relocated into larger facilities, in Oxfordshire, UK. The new building has purpose-built laboratories and doubles the company’s manufacturing capacity. This will increase the speed of new product development within NAC’s core business of infectious disease antigens and antibodies. The new laboratory space also enables NAC to add custom immunoassays to its offering to support customer’s ELISA assay and lateral flow device requirements.
The new suite of laboratories has been established to satisfy increasing commercial demands and accommodate NAC’s growing R&D pipeline. The move facilitates the expansion of the Company’s custom services for recombinant protein production, based on its proprietary mammalian cell expression system. The HEK293 expression system used at NAC has been used to prepare a wide range of complex recombinant proteins, that have been shown to be glycosylated and to demonstrate functional activity.
Dr Nick Roesen, Chief Scientific Officer, NAC, said: “I am delighted with the new facilities and the increased capacity that they provide. The addition of immunoassay development services will enable our customers to work with us from protein expression through to development of an immunoassay for a specific protein. In providing this new service we aim to fill the gap between small-scale R&D expression and high-end pharmaceutical scale GMP manufacturing. We are excited to offer this to our customers, while at the same time progressing our own new product pipeline for infectious disease antigens and anitbodies.”
This article has been republished from materials provided by The Native Antigen Company. Note: material may have been edited for length and content. For further information, please contact the cited source.
Moving Toward a Future Free of Drug-Induced Hearing LossNews
A new special publication orchestrated by five of the nation's leading hearing experts compiles the latest research into hearing loss caused by drugs and solvents - how it occurs, how to treat it, and how to prevent it.READ MORE
Chemicals in Lavender and Tea Tree Oil Could be Hormone DisruptorsNews
A new study lends further evidence to a suspected link between abnormal breast growth in young boys--called prepubertal gynecomastia--and regular exposure to lavender or tea tree oil, by finding that key chemicals in these common plant-derived oils act as endocrine-disrupting chemicals.READ MORE
Huntsman Cancer Institute Joins National Clinical Trial Targeting AMLNews
Huntsman Cancer Institute (HCI) at the University of Utah (U of U) has been selected to participate in the Beat AML Master Trial, an innovative clinical trial sponsored by The Leukemia & Lymphoma Society (LLS). The clinical trial is testing several new targeted therapies for the treatment of patients with acute myeloid leukemia (AML). HCI is the only facility in the Mountain West offering this trial to AML patients.READ MORE
Comments | 0 ADD COMMENT
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018
International Conference on Molecular Biology and Stem Cells
Aug 13 - Aug 15, 2018